Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies

BACKGROUND: Poly-(ADP-Ribose)-Polymerase (PARP) inhibitors are becoming important actors of anti-neoplasic agents landscape, with recent but narrow FDA's approvals for ovarian BRCA mutated cancers and prostatic cancer. Nevertheless, PARP inhibitors are also promising drugs for combined treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Lesueur, Paul, Chevalier, François, Austry, Jean-Baptiste, Waissi, Waisse, Burckel, Hélène, Noël, Georges, Habrand, Jean-Louis, Saintigny, Yannick, Joly, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620324/
https://www.ncbi.nlm.nih.gov/pubmed/28978184
http://dx.doi.org/10.18632/oncotarget.19079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620324/
https://www.ncbi.nlm.nih.gov/pubmed/28978184
http://dx.doi.org/10.18632/oncotarget.19079

Ejemplares similares